Skip to Late-Breaking Abstracts »
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
# | Title | Authors | Category | Keywords |
---|---|---|---|---|
O1 | Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT | Hólmfridur R. Halldórsdóttir, MSc; Lars Ringgaard, PhD; Martin Bak, PhD; Ditte Jæhger, MSc; Esben Christensen, MSc; Fredrik Melander, PhD; Mie L. Hübbe, MSc; Rasmus Eliasen, PhD; Frederikke P. Fliedner, MSc; Andreas Kjaer, MD, PhD; Anders E. Hansen, DVM, PhD; Jonas R. Henriksen, PhD; Thomas L. Andresen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; TLR |
O2 | Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma | Robyn Gartrell, MD; Andrew X. Chen, BS; Emanuelle M. Rizk, BA; Douglas K. Marks, MD; Margaret H. Bogardus, BA; Basil A. Horst, MD; Rui Chang, MD; Anthea Monod, PhD; Raúl Rabadán, PhD; Yvonne Saenger, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
O3 | Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study. | Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Stephen Reeder, BS; Jenny Ashforth, Miss; Melissa Courtney, Miss; Amanda Coutts, PhD; Tressa Hood, MS; Sarah E. Church, PhD; Clare Coveney, PhD; Jan Davidson-Moncada, MD, PhD; Jorn Meinel, MD; Marc Schmitz, MD; Francesco M. Marincola, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune suppression; Leukemia/Lymphoma; Systems biology; Tumor microenvironment |
P3 | Predicting patient response to checkpoint blockade therapy using in vitro 3D cultures | Kathryn Appleton, PhD; Ashley K. Elrod; Qi Jin Guo; Dennis Ruder; Tessa DesRochers, PhD; Tessa DesRochers, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P4 | Novel immune competent murine glioblastoma models derived from Nestin-CreERT2; QuakingL/L; P53L/L; PTENL/L mice | Chao-Hsien Chen, MD; Renee Chin, MS; Genevieve P. Hartley, PhD; Cheng-En Hsieh, MD; Rishika Prasad, MS; Takashi Shingu, PhD; David S. Hong, MD; Jian Hu, PhD; Michael A. Curran, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Myeloid cells; MDSC; T cell; Tumor microenvironment |
P5 | Laminar Wash™ AUTO system: a reliable walk-away sample preparation solution for better TIL recovery without centrifugation | Ira Kim; Melvin Lye; Roberta Zappasodi, PhD; Isabell Schulze; Christoph CE. Eberle, PhD; Chyan Ying Ke; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Taha Merghoub, PhD; Namyong Kim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Clinical trial; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P6 | Development of a peripheral blood mononuclear cells (PBMC) ImmunoGraft platform to evaluate the pharmacodynamics of Immuno-oncology therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma; Vaccine |
P7 | Development of a Natural Killer (NK) ImmunoGraft Platform for the Evaluation of the Pharmacodynamics of Immuno-Oncology Therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Jon Weidanz, PhD; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Immune monitoring; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P8 | Monoclonal antibody detection from formalin-fixed paraffin-embedded tumor tissues using Fab-selective proteolysis nSMOL coupled with liquid chromatography and triple quadrupole mass spectrometry | Takashi Shimada, PhD; Noriko Iwamoto, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Tumor microenvironment |
P9 | Immune checkpoint biomarkers in hepatocellular carcinoma (HCC): Assessment of PD-L1 and tumour mutation burden in tumour samples from clinical patients | Hisani Horne, PhD, MPH; Young S. Lee; Todd Creasy; Rebecca Fish; Jonathan Cairns; Paul Scorer; Janine Feng; Marietta Scott, PhD; Mark Gustavson; Aleksandra Dudek-Madej; Craig Barker; Nicholas Holoweckyi; Rebecca Halpin; Peiyi Wang; Quinea Lassiter; Xiaoling Xia; Mohammed Abdelwahab; Weimin Li; Alejandra Negro; Jill Walker; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immunoscore |
P10 | Inertial Microfluidics Enables Highly Consistent Separation and Concentration of Leukocytes from Human Peripheral Blood for Downstream B-Cell and T-Cell Functional Assays | Sarah M. Mickool; Eric V. Smith; Aleksander J. Jonca; Gustavo Arnal; Mary Vincent Larcom; Melanie Scully; Peng Megn Kou, PhD; Nitin Kulkarni; Kyle C. Smith; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Immune monitoring; T cell |
P11 | Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks | George A. Dominguez, PhD; John Roop; Alexander Aa. Polo, BS; Anthony Campisi, BS; Dmitry I. Gabrilovich, MD/PhD; Amit Kumar, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; MDSC |
P12 | Deep characterization of the depleted plasma proteome in subjects with NSCLC using data independent acquisition mass spectrometry reveal host immune response mechanisms | Nicholas Dupuis, PhD; Linda Sensbach; Sebastian Müller; Lukas Reiter; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Inflammation; Proteomics; Systems biology |
P13 | Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept | Arjun Khunger, MD; Ghanashyam Sarikonda; Paul Frankel, PhD; Jenn Tsau, PhD; Zeni Alfonso, PhD; Jane Gao, MS; Anil Pahuja, BSc; Christine A. Vaupel, PhD; Naveen Dakappagari; Shabnam Tangri, PhD; Ahmad A. Tarhini, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
P14 | Validation of Dendritic Cell and Natural Killer Cell Signatures for Clinical Biomarker Development | Bolan Linghu, PHD; Pei Zhang, PhD; Marylens Hernandez; Mingchao Xie, PhD; Christine Barbon; Srimathi Srinivasan; Deanna Russell, M.S.; Anna Coenen-Stass; Deanna A. Mele, PhD; Patricia McCoon, PhD; Jonathan Dry; Ben Sidders; Kris Sachsenmeier, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Dendritic cell; Gene expression; Immune monitoring; NK/NK T cell |
P15 | Microsatellite instability detection with cell-free DNA next-generation sequencing | Ariane Lozac'hmeur, MS; Jason Perera, PhD; Denise Lau, PhD; Aly Khan, PhD; Ariane Lozac'hmeur, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers |
P16 | Circulating immunological biomarkers for predicting response to neoadjuvant chemotherapy in TNBC patients | Charlotte K. Milton, PhD; Thanussuyah Alaguthurai; Atousa khiabany, Mres; Sheeba Irshad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Chemokine; Chemotherapy; Clinical study; Cytokine; Immune contexture; Immune monitoring; Solid tumors |
P17 | Role of plasma-derived exosome in monitoring immunotherapy response and toxicity | Arnav Mehta, MD PhD; Gyulnara Kasumova; Alvin Shi; Lina Hultin Rosenberg; Emmett Sprecher; Dennie Frederick; Ryan J. Sullivan, MD; Keith T. Flaherty; Nir Hacohen; Genevieve M. Boland; Marijana Rucevic, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Proteomics; Solid tumors |
P18 | Liquid biopsy protein biomarkers to predict responses and elucidate resistance to cancer immunotherapy | Arnav Mehta, MD PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Gyulnara Kasumova; Emmett Sprecher; Lina Hultin Rosenberg; Dennie Frederick; Ryan J. Sullivan, MD; Nir Hacohen; Keith T. Flaherty; Genevieve Boland; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics; Solid tumors |
P20 | Semaphorin 4D in peripheral blood of head and neck squamous cell carcinoma reads the histological pattern of tumor inflammation in real time | Ioana Ghita; Manar Elnaggar; Risa Chaisuparat; John Papadimitriou; Joshua Lubek; Rania H. Younis, B.D.S., MDS., PhD; Soren M. Bentzen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Inflammation; Tumor stroma |
P21 | Activation Profiling of tumor infiltrating CD8+ T cells reveals CTLA-4 mean fluorescence intensity correlates with response in treatment naïve melanoma. | Lauren S. Levine, MD; Katy Tsai, MD; James C. Lee, MD; Clinton Wu, BS; Kelly Mahuron, MD; Alain Algazi, MD; Michael G. Rosenblum, MD PhD; Adil Daud, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P22 | Transcriptomic Characterization of Immune Response within Diverse Tumor Environments using the NanoString® nCounter® PanCancer IO 360™ Assay | Jessica Perez, PhD; Lei Yang; David Henderson, PhD; Heather A. Brauer, PhD; Sarah Warren, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Inflammation; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
P23 | High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF) | Jose C. Villasboas, MD; Kaitlyn R. McGrath, M.S.; El-ad David Amir, PhD; Roberto A. Leon-Ferre, MD; Matthew P. Goetz, MD; Judy Boughey, MD; Jody Carter, MD, PhD; Krishna R. Kalari, PhD; Liewei Wang, MD, PhD; Vera J. Suman, PhD; Richard Weinshilboum, MD; Stephen M. Ansell, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Immune monitoring; Immune suppression; Immune tolerance; Myeloid cells; NK/NK T cell; Solid tumors |
P24 | Molecularly guided digital spatial profiling for highly multiplexed analysis of gene expression with spatial and single cell resolution | Anushka Dikshit, PhD; Chris Merritt, PhD; Jamie Rose Kuhar; Karen Nyugen; Kristina Sorg; Bingqing Zhang; Courtney M. Anderson, PhD; Xiao-Jun Ma; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemokine; Cytokine; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P25 | A Conserved MART-1 T Cell Receptor Motif is Predictive of Responses to Checkpoint Blockade | Ariel Y. Isser, BS.; Tatsuya Yoshida; Junya Ichikawa; Jeffrey S. Weber, MD, PhD; Jonathan P. Schneck, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors; T cell |
P26 | Murine T cell phenotype and function in a single-well format: a novel, multiplexed and high-throughput assay workflow using the iQue platform | Veronica Bruce, PhD; Caroline Weldon; John O'Rourke; Veronica Bruce, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Cytokine; Immune contexture; Immune monitoring; Immune suppression; T cell |
P27 | Functional 3D-plEX quantitative multiplex immunofluorescence platform to assess IO drug impact on tumor microenvironment in ex vivo treated intact 3D-tumor organoids of fresh patient tumor tissue. | Jenny Kreahling, PhD; Vijayendra Agrawal, PhD; Melba Page, PhD; Mibel Pabon, PhD; Soner Altiok, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Cytokine; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P28 | Mass spectroscopy-based highly multiplexed super-resolution imaging method for fine details of tumor microenvironment monitoring and tumor-immune cell interactions | Yunhao Bai, BS; Bokai Zhu; Michael Angelo, MD, PhD; Yongxin Zhao; Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Garry P. Nolan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Systems biology; T cell; Tumor microenvironment |
P29 | Comprehensive Image Analysis of Immunostained NSCLC Tissues Provides Necessary Context for Immune Oncology Biomarker Profiling | Charles Caldwell, Jr., PhD; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhD; Roberto Gianani, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P30 | Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors | Sarah E. Church, PhD; Jason W. Reeves; Daniel R. Zollinger; Jill McKay-Fleisch; Andrew M. White, BSc; Michael D. Bailey; Arya Bahrami, PhD; Chris Merritt, PhD; Margaret Hoang; Sarah Warren, PhD; Joseph M. Beechem, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Monocyte/Macrophage; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P31 | Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow | Carla Coltharp, PhD; Bethany Remeniuk, PhD; Chichung Wang; Rachel Schaefer; Linying Liu; Glenn Milton; Victoria Duckworth; Michael McLane; Peter Miller; Yi Zheng; Carla Coltharp, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P32 | Differential immune contexture of human colorectal carcinomas with mismatch repair deficiency (MSI-H) and increased DNA damage responses (DDR). | Shruti Desai, PhD; Venkata Nagineni; Micaela Morgada; Aravind N. Kalathil; Ila Datar; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P33 | DNA damage response (DDR) is associated with increased adaptive anti-tumor responses and PD-L1 expression in human non-small cell lung cancer. | Shruti Desai, PhD; Aravind N. Kalathil; Roy S. Herbst, MD, PhD; Ranjit S. Bindra; Patricia LoRusso, DO; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
P34 | A fully optimized end-to-end solution for I/O multiplex immunofluorescence staining using Opal Polaris 7-Color PD1/PD-L1 Panel Kits for lung cancer and melanoma | Yi Zheng; Rachel Schaefer; Linying Liu; Glenn Milton; CARLA COLTHARP, PhD; Victoria Duckworth; Victoria Duckworth, MS; Michael McLane; Peter Miller, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P35 | Pick-Seq®: a spatial analysis tool for immuno-oncology biomarker discovery utilizing multi-parameter imaging and RNA sequencing of tissue micro-regions | Nolan Ericson; Rebecca Podyminogin; Jennifer Chow, PhD; Yu-An Chen; Jia-Ren Lin; Zoltan Maliga; Peter Sorger; Kyla Teplitz; Melinda R. Duplessis, PhD; Eric Kaldjian, MD; Tad George, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P36 | The complexity of myeloid-derived suppressor cells in non-small cell lung cancer: A combinatorial multiplex IHC and flow cytometry approach | Amanda Finan, PhD; Muriel Smet; Maroua Tliba; Manon Motte; Jean-Philippe Coton; Domenico Lazzaro; Renaud Burrer; | Biomarkers, Immune Monitoring, and Novel Technologies | MDSC; Tumor microenvironment |
P37 | ImmunoPET imaging of glioma-infiltrating myeloid cells using Zirconium-89-labeled anti-CD11b antibody | Alexandra P. Foster, BS; Rajeev Kumar; Shubhanchi Nigam; Lauren McCarl; Robert S. Edinger; Ian Pollack; Carolyn Anderson; Wilson B. Edwards; Gary Kohanbash; Alexandra P. Foster, BS; | Biomarkers, Immune Monitoring, and Novel Technologies | Monocyte/Macrophage; Myeloid cells; MDSC; Pediatric tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P38 | Sensitive methodologies for tracking T cell immunotherapy by MRI | Brooke M. Helfer, PhD; Deanne Lister; Charles F. O'Hanlon III; Eric Ahrens; Brooke M. Helfer, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; CAR T cells; Solid tumors; T cell; T cell lineages |
P39 | Looking beyond the assay: Comparison of multiplex chromogenic and fluorescent immunohistochemistry for standardized immune oncology profiling in non-small cell lung carcinoma patients | Ana Hidalgo Sastre, PhD; Lorenz Rognoni, PhD; Monika Baehner; Marco Testori; Jessica Chan; Andreas Spitzmüller; Nicolas Brieu, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Inflammation; Monocyte/Macrophage; T cell; Tumor microenvironment; Tumor stroma |
P40 | Tumour immunity signatures to expand current diagnostic approaches in mismatch repair deficient cancers in the context of Lynch Syndrome through InSituPlex technology and Tissue Phenomics integration | Ryan A. Hutchinson, Fellow; Armin Meier, PhD; Bonnie Philips; Katir K. Patel, PhD; Sean R. Downing, PhD; Karan Sharma; Julia Como; Simin Daneshvar; Gillian Livock; Ingrid M. Winship; Christophe Rosty; Mark Jenkins; Gunter Schmidt; Daniel D. Buchanan; Ryan A. Hutchinson, Fellow; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P41 | Multiplexed Imaging for the simultaneous detection of nucleic acids and proteins to dissect the tissue immune landscape and microenvironment of viral diseases | Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Chi Ngai Chan, PhD; Bokai Zhu; Yunhao Bai, BS; Marc Bosse, PhD; David McIlwain, PhD; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; Jacob Estes, PhD; Garry P. Nolan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Leukemia/Lymphoma; Proteomics; Systems biology; T cell; Tumor microenvironment |
P42 | An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors | Tyvette S. Hilliard; Nicholas Stavrou; Erinn Parnell; Judy Kuo; Eric Leones; Flora Sahafi; Josette William, PhD, MD; Sharon Stack; Anna Juncker-Jensen; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P43 | A novel platform for highly multiplexed, single-cell imaging of cell suspensions | Anum Khan; Won-Mean Lee; Jon Mulholland; Anum Khan; Dhananjay Wagh; John Coller; Gabriel Mercado; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Proteomics; T cell |
P44 | Solar-IHC: Cell-to-cell distances in the tumour immune microenvironment of Hepatocellular Carcinoma has the potential to prognosticate survival | Matthew Leong, N.A.; Toh Han Chong; Choo Su Pin; Kiat Hon Lim Tony; Joycelyn Lee; David Wai; Poh Sheng Joe Yeong; Jin Miao Chen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Cytokine; Immune contexture; Solid tumors; T cell; Tumor microenvironment |
P45 | Multiplex Immunofluorescence Staining, Whole Slide Imaging, and Spatial Phenotyping of T-cell Exhaustion, Regulatory T cells, and Myeloid-Derived Suppressor Cells in Tumor FFPE Samples | Katherine lillard, PhD; Kyla Teplitz; Katir K. Patel, PhD; Michael Tomac, MS; Kate Lillard, PhD; Anne Hellebust, PhD; Mael Manesse, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P46 | Same-slide multiplex immunofluorescence and brightfield histological staining as a new research tool for fast and comprehensive pathology assessment of the tumor microenvironment | Mael Manesse, PhD; Douglas Wood, PhD; Heike Boisvert, PhD; Sean R. Downing, PhD; Mael Manesse, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune contexture; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
P47 | Imaging cancer immunology: Systemic tracking of immune cells in vivo with magnetic particle imaging | James R. Mansfield, Msc; Gang Ren; Jeff Gaudet; Yanrong Zhang; Sara N. Ghobadi; James R. Mansfield, Msc; Max Wintermark; Patrick Goodwill; | Biomarkers, Immune Monitoring, and Novel Technologies | Immune monitoring; Inflammation; Monocyte/Macrophage; Solid tumors |
P48 | Turning ‘cold’ tumours ‘hot’: Guided magnetic hyperthermia for tumour immune stimulation | Patrick Goodwill; Daniel Hensley; Zhi Wei Tay; Elaine Yu; James R. Mansfield, Msc; James R. Mansfield, Msc; Blayne Kettlewell; Ryan Orendorff; Kyle Fields; Steve Conolly; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune adjuvant; Inflammation; Solid tumors; Tumor microenvironment |
P49 | Use of Ultivue InSituPlex® multiplex immunofluorescence to localize and quantify regulatory T lymphocytes in formalin-fixed paraffin-embedded human tissue sections | Shawn P. O'Neil, DVM, PhD; Renee E. Huynh; Courtney Hebert; Jamie Buell; Sean R. Downing, PhD; John L. Jakubczak, PhD; Yutian Zhan, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Autoimmunity; Inflammation; Regulatory T cell (Treg cell); T cell; T cell lineages |
P50 | Rapid high-plex staining and simultaneous imaging for immunophenotyping of tissue sections | Benjamin Pelz, PhD; Daniel Migliozzi; Diego G. Dupouy; Anne-Laure Leblond; Alex Soltermann; Martin AM. Gijs, Prof.; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; B cell; Biomarkers; Dendritic cell; Granulocyte; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P51 | Phenotypic and Spatial Analysis of Inter- and Intra-tumor Heterogeneity Using Multiplexed Ion Beam Imaging (MIBI) | Jason Ptacek, PhD; Robert Johnson, PH.D; Joann Palma, PH.D; Jay Tarolli; Rachel Finck; Murat Aksoy; Yi Zhang; Jessica Finn; Jason Ptacek, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P52 | CyTOF in anti-ILT3 mAb drug discovery - humanized tumor model selection and in vivo PD/biomarker exploration | Yujie Qu, MD; Alan Byford; Caniga Michael; Ying Huo; Barbara Joyce-Shaikh, BS.; Laurence Fayadat-dilman; Veronica Juan; Carl Mieczkowski; Laura Bald; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Stephen Alves; Lily Moy; Philip E. Brandish, PhD; Jie Zhang-Hoover; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs) |
P53 | Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from IHC images | Sripad Ram, PhD; Amy-Jackson Fisher; Pamela Whalen; Cory Painter; Pamela Vizcarra; Eric L. Powell, MD; Sripad Ram, PhD; Sripad Ram, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
P54 | Development of a 9-color immunofluorescence assay using tyramide signal amplification and multispectral imaging for high-throughput studies on FFPE tissue sections | Bethany Remeniuk, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Clifford C. Hoyt, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P55 | Combining the best of two worlds: Transfer of multiplex immunofluorescence images from non-small cell lung carcinoma patients into pseudo multiplex chromogenic immunohistochemistry images | Lorenz Rognoni, PhD; Ana Hidalgo Sastre, PhD; Ana Hidalgo Sastre, PhD; Linda Brützel; Philipp Wortmann; Monika Baehner; Marco Testori; Jessica Chan; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Carcinogenesis; Immune contexture; Inflammation; Monocyte/Macrophage |
P56 | Interrogating the effect of oncolytic Herpes simplex virus-1 on spatial arrangement of myeloid cells in glioblastoma multiforme using an ex vivo human system and multiplex immunohistochemistry | Munisha Smalley, PhD; Misti Jain, PhD; Saravanan Thyiagarajan; Emily Alonzo; Katherine Crosby; Douglas Best; Hans Gertje, BS; Basavaraja U. Shanthappa; Ralph Pulchalski; Charles Cobbs; E. Antonio Chiocca; Sean Lawler, PhD; Aaron Goldman; Munisha Smalley; | Biomarkers, Immune Monitoring, and Novel Technologies | Dendritic cell; Immune monitoring; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P57 | An ex-vivo human system elucidates a role for natural killer cells in the anticancer effect of drug combinations in triple negative breast cancer | Aaron Goldman; Douglas Best; Saravanan Thiyagarajan; Misti Jain, PhD; Basavaraja U. Shanthappa; Munisha Smalley, PhD; Hans Gertje, BS; Aaron Goldman; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor stroma |
P58 | Brain MRI Performed within 4 Weeks of PD-1 Inhibitors as a Potential Prognostic Marker for Non-small Cell Lung Cancer (NSCLC) | Ammar Sukari, MD; Misako Nagasaka, MD; Seongho Kim, PhD; Tahmida Chowdhury; Natasha Robinette, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
P59 | Highly Consistent automated multiplex immunofluorescence for immunoprofiling of solid tumors in clinical trials: assay validation study using multispectral imaging and digital analysis. | Jaime Rodriguez-Canales, MD; Michael J. Surace, PhD; Lorenz Rognoni, PhD; Farzad Sekhavati; Andrew Fisher, PhD; Andreas Spitzmueller; Sara Batelli, PhD; Karma Dacosta; Vinay Pawar; Clifford Hoyt; Edwin R. Parra, MD., PhD; Jaime Rodriguez-Canales, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Solid tumors |
P60 | Combining transcriptomic immune population inference with automated digital masking of H&E images finds immune effectors preferentially distribute within stroma regions | Christopher W. Szeto, PhD; Mustafa Jaber, PhD; Liudmila Beziaeva; Kevin Kazmierczak; Steve Benz; Shahrooz Rabizadeh; | Biomarkers, Immune Monitoring, and Novel Technologies | MDSC; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
P61 | Segmentation and Classification of Single Cells using Multiplexed Ion Beam Imaging | Jay G. Tarolli; Jay Tarolli; Jay Tarolli; Rachel Finck; Murat Aksoy; Yari Sigal; Noah Newgren; Jessica Finn; Jason Ptacek, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; T cell; Targeted therapy; Tumor microenvironment |
P62 | Bringing the tumor microenvironment into focus: Simplified development of seven-color multiplex immunohistochemistry-Immunofluorescence (mIF) panels | Melissa Whiteman, PhD; Eric McIntush, PhD; Mike Spencer; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
P63 | Clinical Assay Development and Validation of Multiplex Immunofluorescent (mIHC) Marker Panel for Evaluation of Tumor Infiltration Myeloid Cells in FFPE Tissue Sections | Lan Yi, Ph.D; Jonathan Juco, MD; Ashhad Mahmood, MD; Omar F. Laterza; Charo Garrido; Lan Yi, Ph.D; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Granulocyte; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
P64 | Highly multiplexed single-cell spatial analysis of FFPE tumor tissues using CODEX® | Jessica X. Yuan, PhD; Gajalakshmi Dakshinamoorthy; Joseph Kim; Sejal Mistry; Nadya Nikulina; Roya Bashier; Cassandra Hempel; Maria Elena Gallina; Julia Kennedy-Darling; Jessica X. Yuan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor microenvironment; Tumor stroma |
P65 | Mutation-Targeted T Cell Responses in Blood from Patients with Solid Tumors Prior to Treatment and which Evolve with Clinical Benefit from Anti-PD-1 Therapies | Benjamin T. Yuen, PhD; Fangfang Yin, PhD; Duo An, PhD; Boi Quach; Linlin Guo, PhD; Joanne BL. Tan, PhD; Songming Peng, PhD; Zheng Pan, PhD; Olivier Dalmas, PhD; Robert Bao, PhD; Kyle Jacoby, PhD; Barbara Sennino, PhD; Stefanie J. Mandl, PhD; Matt Walters, PhD; Juan C. Jaen, PhD; Alex Franzusoff, PhD; Benjamin T. Yuen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
P66 | A novel mass cytometry-based immunomonitoring platform for characterizing the peptide vaccine-induced immune response of HLA-A*0201+ patients with K27M+ diffuse midline gliomas | Jared Taitt, BA; Payal Watchmaker, PhD; Takahide Nejo, MD, PhD; Neil Almeida; Kaori Okada; Sabine Mueller, MD PhD; Hideho Okada, MD, PhD; Jared Taitt, BA; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical trial; Immune monitoring; Immune suppression; MDSC; Neoantigens; Pediatric tumors; T cell; Vaccine |
P67 | Use of a Regional Integrated Health Record Data Network to Identify Patients who Received Checkpoint Therapy Following Cancer Diagnosis as a Foundation for Exploring Immunotoxic Events | Theresa Walunas, PhD; Carlos Galvez; Saya Jacob; Jeffrey A. Sosman, MD; Abel Kho; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Epidemiology; Immune toxicity |
P68 | Innate inflammatory pathways are associated with TIL growth and response to adoptive immunotherapy | Suhendan Ekmekcioglu, PhD; Dai Ogata, MD, PhD; Caitlin Creasy, MS; Marie A. Forget, PhD; Sun-Hee Kim, PhD; Jason Roszik, PhD; Mike Spencer; Patrick Hwu, MD; Elizabeth A. Grimm, PhD; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Immune suppression; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P69 | Highly multiplexed single cell spatial analysis of the tumor microenvironment in lymphoma | Monirath Hav, MD, PhD; Anthony Colombo; Erik Gerdtsson; Mohan Singh; Denaly Chen; Imran Siddiqi, MD PhD; James Hicks; Peter Kuhn, PhD; Akil Merchant, MD; Akil Merchant, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Immune contexture; Leukemia/Lymphoma; Tumor microenvironment |
P70 | Tissue-based characterization of T cell exhaustion in inflammatory bowel disease and colorectal cancer using multiplex IHC | Marina Bleck, PhD; Diane Mierz; Ania Mikucki; Marie Marcher; Sidharth Kerkar, MD; Gerald Nabozny, PhD; Sean R. Downing, PhD; Alexander C. Klimowicz, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Autoimmunity; Biomarkers; Checkpoint blockade; Inflammation; T cell |
P71 | Refining tumor mutation burden values using variant expression | Shannon T. Bailey, PhD; Muhammad Ekram, PhD; Jim Lund; Jeffrey R. Gulcher; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
P72 | Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms | Dattatreya Mellacheruvu, PhD; Rachel Pyke; Charles Abbott, PhD; Nick Phillips; Rena McClory; John S. West, MBA; Richard Chen; Sean M. Boyle, PhD; Dattatreya Mellacheruvu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Neoantigens; Proteomics; Vaccine |
P73 | Large scale multiomics reveals a marked bias in driver mutations toward areas not reliably presented to the immune system | Alex S. Powlesland, PhD; Michael J. Cundell, PhD; Floriana Capuano, PhD; Brandon W. Higgs; David Lowne, BS; Ricardo J. Carreira, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Neoantigens; Proteomics; T cell; Targeted therapy; Tumor antigens |
P74 | Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patient compared to their tumor mutation burden | Guilhem Richard, PhD; Randy F. Sweis, MD; Matthew Ardito, BA; Tzintzuni Garcia; Leonard Moise, PhD; Michael F. Princiotta, MS, PhD; Dominique Bridon; William Martin, BA MD; Gad Berdugo, MSc, MBA; Arjun Balar; Gary Steinberg; Anne S. de Groot, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell |
P75 | targetSCAPE and ultraSCAPE: Simultaneous identification and deep profiling of human antigen-specific T cells and other immune cell subsets by mass cytometry | David Roumanes, PhD; Faris Kairi; Alessandra Nardin, DVM; Evan Newell, PHD; Michael Fehlings; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Neoantigens; T cell |
P76 | Development of immunopeptidomic platform for human leucocyte antigens class I using microflow liquid chromatography and quadrupole time-of-flight mass spectrometry | Takashi Shimada, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; Takashi Shimada, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Neoantigens; Proteomics; Tumor antigens |
P77 | Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms | Charles Abbott, PhD; Eric Levy, PhD; Rachel Pyke; Rena McClory; Sekwon Jang, MD; Richard Z. Chen, PhD; Sean M. Boyle, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Neoantigens; T cell; Tumor microenvironment |
P78 | Optimization of Tumor Mutation Burden Measurement in FFPE DNA | Janice K. Au-Young, PhD; Iris Casuga, PhD; Vinay Mittal; Dinesh Cyanam, MS; Elaine Wong-Ho; Fiona Hyland; Seth Sadis; Warren Tom, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors |
P79 | Molecular comparison of tumor microenvironment in primary lung, melanoma, and kidney tumors versus paired lung metastases reveals shared perturbations of the immune milieu during oligoprogression | Davide Bedognetti, MD, PhD; Jessica Roelands, Master; Angelo Manfredi; Norma Maugeri; Francesca De Nicola; Ludovica Ciuffreda; Matteo Pallocca; Maurizio Fanciulli; Francesca Di Modugno, PhD; Paolo Visca; Barbara Antoniani; Gabriele Alessandrini; Darawan Rinchai, PhD; Wouter RL. Hendrickx, PhD; Paola Nistico', MD; Gennaro Ciliberto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune contexture; Tumor infiltrating lymphocytes (TILs) |
P80 | HER2 is associated with prolonged survival in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade | Carrie B. Brachmann, PhD; Emon Elboudwarej; Manish Shah, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Jingzhu Zhou; Dung Thai; Pankaj Bhargava; Daniel V. Catenacci, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
P81 | Association of tumor mutational burden with clinical, genomic, and treatment characteristics in advanced non-small cell lung cancer | Connor Willis, PharmD; Hillevi Bauer, PharmD; Trang H. Au, PharmD; Sudhir Unni, PhD, MBA; Wallace Akerley, MD; Ashley Sekhon, MD; Firas Badin, MD; John L. Villano, MD, PhD; Matthew B. Schabath, PhD; Bing Xia, MD; Beth Gustafson, PharmD; Komal Gupte-Singh, PhD; Beata Korytowsky; John-michael Thomas, PharmD; Gabriel Krigsfield, PhD; Solomon J. Lubinga, PhD; diana brixner, PhD; David Stenehjem, PharmD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
P82 | High-throughput pairing of single T-cell α and β chains along with phenotypic expression profiling | Brittany Brown, BS; Miranda Byrne-Steele, PhD; Wenjing Pan, PhD; Song Li; Mary Eisenhower, BS; Daniel Weber; Mollye Depinet, MS; Xiahong Hou, PhD, MD; Alex Moore; Jian Han, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; CAR T cells; Gene expression; Immune monitoring; Immune tolerance; Regulatory T cell (Treg cell); T cell; T cell lineages; Targeted therapy |
P83 | Pan-cancer assessment of composite genomic biomarkers in immuno-oncology to predict responses and resistances to immune checkpoint inhibitor therapy | Gustavo C. Cerqueira; Laurel A. Keefer; Kelly Gerding, PhD; Kenneth Valkenburg; Christina Oliveras; James R. White; Leila Ettehadieh; Christopher Gault; James Hernandez; Eric Kong; Isabell Loftin; Samuel Angiuoli; Abigail McElhinny; John K. Simmons, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Solid tumors; Tumor evasion |
P84 | Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers | San-chi Chen, MD; Kien-Thiam Tan, PhD; Ming-Huang Chen; Yi-Ping Hung, MD; Yi-Lin Hsieh; Yi-Hua Jan; Yee chao; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
P85 | Development of a pan-cancer NGS assay for detection of tumor mutational burden and targeted biomarkers from FFPE samples | Dinesh Cyanam, MS; Vinay Mittal; Nickolay Khazanov; Paul Williams; Janice Au-Young; Gary Bee; Sameh El-Difrawy; Aren Ewing; Jennifer Kilzer; Anelia kraltcheva, Ph.D; Scott Myrand, MS; Yu-Ting Tseng; Cristina Van Loy; Elaine Wong-Ho; Chenchen Yang; Dinesh Cyanam, MS; Warren Tom, PhD; Santhoshi Bandla; Seth Sadis; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Immune monitoring; Solid tumors; Targeted therapy |
P86 | Predictive Immune Modeling enables biomarker discovery in NSCLC patients treated with second line immunotherapy | Natalie A. LaFranzo, PhD; Steve Daniel, PhD; Walt Carney, PhD; Milan Bhagat; Natalie A. LaFranzo, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P87 | All-in-One, quantitative immune repertoire profiling of PBMC and FFPE for renal cancer treatment evaluation | Mollye Depinet, MS; Wenjing Pan, PhD; Sang-gin Wu, MD, PhD; Xiaohong Hou, MD PhD; Brittany Brown, BS; Mary Eisenhower, BS; Daniel Weber; Miranda Byrne-Steele, PhD; Michael Lotze; Jian Han, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; B cell; Cytokine; Immune monitoring; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
P88 | Evaluation of a tumor-only pan-cancer targeted semi-conductor based next-generation sequencing (NGS) test for microsatellite instability in FFPE samples | Sameh El-Difrawy, Ph. D; Anelia kraltcheva, Ph.D; Vinay Mittal; Elaine Wong-Ho; Dinesh Cyanam, MS; Seth Sadis; Jennifer Kilzer; Cristina Van Loy; Janice Au-Young, PhD; Aren Ewing; Sameh El-Difrawy; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Solid tumors |
P89 | Obesity related changes in AXL-driven inflammatory signaling impact survival in melanoma | Alicia A. Gingrich, MD; Alexander Merleev, PhD; Kylie Abeson, BS; Robert Canter, MD, MAS, FACS; Emanual Maverakis; Amanda Kirane, MD; Alicia A. Gingrich, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune monitoring; Inflammation; Tumor microenvironment |
P90 | Unique tumor immune microenvironments of potentially PD-L1/TGF-β trap responsive tumors | Sean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Inflammation; Tumor microenvironment |
P91 | Expression profiling of T cells using nanoscale automation with a full-length RNA sequencing library preparation kit on a microfluidic circuit platform | Thomas J. Goralski, PhD; Sangpen J. Chamnongpol; Michael J. Phelan; Jennifer Snyder-Cappione; Julie J. Alipaz; Joel J. Brockman; Brian J. Fowler; Jennifer A. Geis; Christopher J. Kubu; Raphael J. Kung; Benjamin J. Lacar; Naveen Ramalingam, PhD; Mandi Wong; Charles J. Park; David J. King; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression |
P92 | Survival Benefits of Comprehensive Genomic Profiling and Treatment in Metastatic Non-Small Cell Lung Cancer | Alison Sexton Ward, PhD; Jennifer Johnson, MD; Komal Gupte-Singh, PhD; Mohammad Ashraf Chaudhary, PhD; Devender Dhanda, PhD; Oliver Diaz, PhD; Katherine Batt, MD, MSc; John Fox; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
P93 | The advanced immune-centric NGS cohort for colon cancer. | Wouter RL. Hendrickx, PhD; Jessica Roelands, Master; Peter Kuppen; Francesco M. Marincola, MD; Najeeb Syed; Davide Bedognetti, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Gene expression; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P94 | A potential mechanism of anti-cancer immune response activated by immune-related adverse events (irAEs) in urological cancer patients | Taigo Kato, MD, PhD; Motohide Uemura; Koji Hatano; Atsunari Kawashima; Takeshi Ujike; Kazutoshi Fujita; Kazuma Kioytani; Norio Nonomura; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; T cell; Tumor antigens |
P95 | Single-cell RNA-sequencing from clinically relevant core needle biopsies for evaluation of tumor-immune cell interactions in the tumor microenvironment | Namit Kumar, PhD; Mohan Bolisetty; Peter Szabo, PhD; Xuan Li; Becky Penhallow; Ryan Golhar; Alice M. Walsh; Saumya Pant; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P96 | T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome | Eric Levy, PhD; Pamela Milani; Sean M. Boyle, PhD; Gabor Bartha; Charles Abbott, PhD; Robert Power; Rena McClory; Robin Li; John S. West, MBA; Richard Chen; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P97 | TCRB repertoire convergence and clonal expansion define the NSCLC tumor microenvironment of responders to anti-PD-1 monotherapy | Timothy Looney, PhD; Katharina Leonards; Ilaria Alborelli; Luca Quagliatta; Philip Jermann; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P98 | Automated rarefaction analysis for precision human and mouse B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved specimens | Timothy Looney, PhD; Geoffrey M. Lowman, PhD; Michelle Toro; Jayde Chang; Denise S. Topacio-Hall, BS, MA; Loni Pickle, PhD; Fiona Hyland; Timothy Looney, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Immune monitoring; T cell; Tumor microenvironment |
P99 | TMBler: a bioinformatic tool for measuring and optimizing Tumor Mutational Burden quantification from targeted sequencing panels | Laura Fancello; Luca Mazzarella, MD PhD; Alessandro Guida; Arnaud Ceol; Piergiuseppe Pelicci; Luca Mazzarella, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens |
P100 | Impact of obesity on immunity in gastroesophageal adenocarcinoma [GEAC] | Sarbajit Mukherjee, MD, MS; Sami Ibrahimi; Yali Zhang; Jianmin Wang; Pawel Kalinski, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Solid tumors |
P101 | Immune-based classification of pleural malignant mesothelioma by using integrative transcriptome analysis. | Ernest Nadal, MD, PhD; Ania Alay; David Cordero; Elisabeth Aliagas; José C. Ruffinelli; Ramón Palmero; Ricard Ramos; Ivan Macía; Anna Ureña; Fran Rivas; Xavier Solé; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P102 | CT antigens are frequently expressed non-inflamed tumors | Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Sean T. Glenn, PhD; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Neoantigens; Tumor microenvironment; Tumor stroma |
P103 | Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing | Jason Perera, PhD; Brandon Mapes, PhD; Denise Lau, PhD; Ameen Salahudeen; Aly Khan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Bioinformatics; Biomarkers; Tumor evasion |
P104 | Impact of chemotherapy (chemo) on peripheral T-cell diversity and implications for subsequent immunotherapy response in breast cancer | Joanna Pucilowska, PhD; Paul Fields, PhD; Valerie K. Conrad, BS; David B. Page, MD; Alison K. Conlin, MD; Joanna Pucilowska, PhD; Catherine Sanders, PhD; Raina A. Tamakawa, MS; Brie M. Chun, MD; Isaac K. Kim, MD; Mark Schmidt; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Clinical study; Immune monitoring; T cell |
P105 | PD-L1 isoform as a potential biomarker to predict response for anti-PD-(L)1 treatment | Kunbin Qu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Tumor evasion |
P106 | Tumor Mutational Burden profile (TMB) of Oncogenic Driver Mutations in Non Small Cell Lung Cancer | Nitika Sharma; Paul R. Walker, MD; Nitika Sharma; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; Targeted therapy |
P107 | Changes in tumor mutational burden in serially biopsied non-small cell lung cancer | James W. Smithy, MD, MHS; David H. Hwang, MD; Yvonne Li; Liam Spurr; Andrew D. Cherniack, PhD; Lynette M. Sholl; Mark Awad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Solid tumors |
P108 | Working Towards Precision Medicine of the Tumor Microenvironment | Kristen Strand-Tibbitts, PhD; Kyung Kim, PhD; Jeeyun Kim; Seung-Tae Kim; Jung-Yong Hong; Laura Benjamin; Kristen Strand-Tibbitts, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Solid tumors; Targeted therapy; Tumor microenvironment |
P109 | Predictive performance of a CD8-derived signature by gene expression profiling in patients with urothelial carcinoma from CheckMate 275 | Peter Szabo, PhD; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Robin H. Edwards, PhD; Saumya Pant; Abdel Saci; Neeraj Adya; Matthew D. Galsky, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
P110 | Tumor CD8+ T-cell infiltration assessed by gene expression profiling alone or by immunohistochemistry plus epithelial-mesenchymal transition gene expression in urothelial carcinoma in CheckMate 275 | Peter Szabo, PhD; Abdel Saci; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Scott D. Chasalow; Michael Montalto; Robin H. Edwards, PhD; Saumya Pant; Neeraj Adya; Bruce Fischer, MD; Matthew D. Galsky, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
P111 | Clinical and Immunologic Implications of a Microsatellite Instability Score in Lung Cancer | Pedro Viveiros, MD; Misuk Lee; Bhoomika Sukhadia, MD; Kyunghoon Rhee; Victor Wang; Jeffrey Chuang; Young Kwang Chae, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immunoscore; Neoantigens; Solid tumors |
P112 | A new way of immunity exploration by linking highly multiplexed antigen recognition to immune repertoire and phenotype | Dagmar Walter, PhD; Stephane C. Boutet; Michael JT. Stubbington, PhD; Katherine A. Pfeiffer; Josephine Y. Lee; Luz Montesclaros; Julia K. Lau; Daniel P. Riordan; Alvaro Martinez Barrio; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Biomarkers; Gene expression; Genetic polymorphism; T cell; T cell lineages |
P113 | Dynamic analysis and visualization of the immune infiltration in human cancer by integrating TCGA data | Mingchao Xie, PhD; Bolan Linghu, PHD; Zhongwu Lai, PhD; Jonathan Dry; Ben Sidders; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Immune contexture; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P114 | TISSUTAL IMMUNE PROFILE AND PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER. | Andrea Botticelli, MD; Bruna Cerbelli; Simone Scagnoli; Maria Ida Amabile; Alessandro De Luca; Lucio Fortunato; Leopoldo Costarelli; Marianna Nuti, PhD; Giulia D'Amati; Paolo Marchetti; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Chemotherapy; Immune adjuvant; Immune suppression; Immunoscore; Tumor microenvironment |
P115 | Deep proteomic characterization of FFPE tumor samples from late-stage melanoma subjects treated with anti-PD-1 immunotherapy | Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele; Antonio Sorrentino; Vito Vanella; Daniel Heinzmann; Paolo Antonio A. Ascierto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Systems biology |
P116 | Centrifuge-free red blood cell lysis and immunostaining of whole blood for flow cytometry using Laminar Wash™ system | Ira Kim; Melvin Lye; Chyan Ying Ke; Nadiezda Fernandez Oropeza; Sigeeta Rajaram; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Namyong Kim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune suppression; Metabolism; NK/NK T cell; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P117 | Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project | Florence Monville, PhD; Frederic Vely; Joseph Ciccolini; Florence Sabatier; Stephane Garcia; Vanina Leca; Marion Fabre; Christelle Piperoglou; Pernelle Outters; Laurent Arnaud; Laurent Vanhille, PhD; Caroline Lauge, BA; Anna Martirosyan, Dr; Aurelie Collignon; Marie Roumieux; Julien Mazieres; Maurice Perol; Françoise Dignat-George; Eric Vivier; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune contexture; Immune monitoring; Immunoscore; MDSC; Tumor infiltrating lymphocytes (TILs) |
P118 | HYDRA platform development to investigate Siglec-engaging tumor immunosuppressive glyco-codes | Li Peng, PhD; Adam Petrone; Adam Shoemaker; Jillian Prendergast, PhD; Zakir Siddiquee; Jenny Che; Lihui Xu, BS; Karl Normington, PhD, MBA; James Broderick; Li Peng, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Tumor evasion; Tumor microenvironment |
P119 | Analytical validation of run-to-run and site-to-site performance of a human immune profiling assay and automated data analysis solution for CyTOF mass cytometry technology | Clare Rogers, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Granulocyte; Immune contexture; Immune monitoring; Myeloid cells; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
P120 | Evaluation of CD8 score by automated quantitative image analysis in metastatic melanoma treated with PD1 blockade: preliminary results | Anjali Rohatgi, MD PhD; Douglas Hartman; Arivarasan Karunamurthy; Julie Burkette; Yana G. Najjar, MD; John M. Kirkwood, MD; Hassane M. Zarour, MD; Liron Pantanowitz; Diwakar Davar, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P121 | Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture | Thomas Sbarrato, PhD; Laurent Vanhille, PhD; Mounia Filahi; Anna Martirosyan, Dr; Véronique Frayssinet; Caroline Davin, BA; Caroline Laugé; Assil Benchaaben; Alboukadel Kassambara; Felipe Guimaraes; Régis Perbost; Jérôme Galon; Hélène Girardi; Jacques Fieschi, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immune suppression; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P122 | Microfluidic-based Cell Separation Method Improves Workflow for Evaluation of Rare Lymphocytes from Cancer Patient Samples | Jodi Stone, BS.; Megan E. Nichols, AAS in Biotechnology; Amy Austin; Kala Bradshaw; Jessica E. Norris, BS, MT; Jennifer Montague, PhD; Peng Meng Kou, PhD; Nitin Kulkarni; Nirav Sheth; Anya Manning, MBA; Sarah M. Mickool; Kyle C. Smith; Ravi Kapur; John D. Powderly, II, MD, CPI; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; T cell |
P123 | Identification of mRNA signatures that predict response to immunotherapy in melanoma patients | Ioannis A. Vathiotis, MD; Amy Sullivan; Sarah Warren, PhD; Nicole Gianino; Sandra Martinez-Morilla, PhD; Pok Fai Wong, MD, MPhil; Harriet Kluger, MD; Konstantinos N. Syrigos; David L. Rimm, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Inflammation; NK/NK T cell; Tumor microenvironment |
P124 | A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Claire Gormley; | Biomarkers, Immune Monitoring, and Novel Technologies | T cell; Targeted therapy |
P125 | ADENOSINE AND AMP GENE EXPRESSION PROFILES PREDICT RESPONSE TO ADENOSINE PATHWAY THERAPIES AND INDICATE A NEED FOR DUAL BLOCKADE OF CD73 AND A2AR WITH CD73 INHIBITORS. | Stephen Willingham, PhD; Drew Hotson, PhD; Jessica Hsieh; Brian Munneke; Long Kwei, PhD; Joseph J. Buggy; Richard A. Miller, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune suppression; MDSC; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
P126 | Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling | Jon Zugazagoitia, MD; Swati Gupta, PhD; Kit Fuhrman, MS PhD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; NK/NK T cell; T cell |
P127 | Development of a 12-marker immunofluorescence multiplex panel for the in-depth investigation of the tumor immune landscape analyzing 4,096 phenotypes | Courtney Hauck; Aditi Sharma; Monique Johnson; Wenya Yang; Bonnie Phillips, PhD; Mark Burton, HTL ASCP; Douglas Wood, PhD; Stephanie Hennek, PhD; Mael Manesse, PhD; J Kent Moore, PhD; Katir K. Patel, PhD; Jamie Buell; Sean R. Downing, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Immune contexture; Monocyte/Macrophage; NK/NK T cell; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P128 | Pooled analysis of Programmed Death Factor Ligand 1 (PD-L1) expression as a predictive biomarker using individual data on 7,918 randomized study patients | Andrea Arfe; Geoffrey Fell; Brian Alexander, MD MPH; Mark Awad, MD PhD; Scott J. Rodig, MD, PhD; Lorenzo Trippa; Jonathan Schoenfeld, MD, MPH; Jonathan Schoenfeld, MD, MPH; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Solid tumors |
P129 | Correlation of circulating CD8 T cell activation with response to immunotherapy in advanced renal cell carcinoma | Jennifer Carlisle, MD; Caroline S. Jansen, BS; Adriana M. Reyes; Nataliya Prokhnevska, BS; Deborah Baumgarten, MD; Viraj A. Master, MD, PhD; R. Donald Harvey, PharmD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Mehmet A. Bilen; Haydn T. Kissick; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell |
P130 | Melanoma patients harbor pre-existing IgG autoantibodies targeting neuronal proteins that associate with differential clinical outcomes following checkpoint blockade | Tyler Hulett, PhD; Michael Gowen, MD; Keith Giles; Danny Simpson; Jeremy Tchack; Una Moran; Zarmeena Dawood; Anna C. Pavlick, MD, MBA; Shaohui Hu; Hua Zhong; Michelle Krogsgaard; Tomas Kirchhoff, PhD; Iman Osman; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Proteomics; Tumor antigens |
P131 | Single cellular interrogation of tumor microenvironment enables diagnosis and prognostication of malignancies | Wei Jian Tan; Jian Hang Lam; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tony Kiat Hon Lim; Joe Poh Sheng Yeong; Tong Seng Lim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Biomarkers; Clinical study; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P132 | Harmony: Integrative tool to analyse and visualise Multiplex-Immunofluorescence Single-Cell Data | Duoduo Wu; Joe P. Yeong, MBBS, PhD; Grace S. Tan; Marion Chevrier; Josh J. Loh; Tony K. Lim; Jinmiao Chen; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor microenvironment |
P133 | High tumor expression of DKK1 is associated with improved clinical benefit and longer progression free survival across multiple solid tumors when treated with a targeted anti-DKK1 antibody (DKN-01) | Michael Kagey, PhD; Girish Naik, MD; Michael Haas, PhD; Heidi Heath; Franziska Schurpf-Huber; Walter Newman, PhD; Cynthia Sirard, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; NK/NK T cell; Solid tumors |
P134 | Prognostic value of tumor microenvironment based on PD-L1 expression and CD8+ TILs density in locally advanced NSCLC treated with concurrent chemoradiotherapy | Lukas Kaesmann, MD; Kathrin Gennen; Julian Taugner; Chukwuka Eze; Monika Karin; Olarn Roengvoraphoj; Jens Neumann; Amanda Tufman; Michael Orth; Simone Reu; Claus Belka; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P135 | Studying Loss of Y chromosome in colorectal and prostate cancers in males for non-invasive cancer biomarkers | AMBREEN ASIM, PhD; Sarita Agarwal; Rakesh Kapoor; Neeraj Rastogi; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers |
P136 | Quantitative/spatial analysis of Tregs reveal a prominent biomarker role in human non-small cell lung cancer (NSCLC) | Richa Gupta, BS; Nicolas Rodriguez-Arriagada; Shruti Desai, PhD; Konstantinos N. Syrigos; Roy S. Herbst, MD, PhD; Vamsidhar Velcheti, MD FACP; David L. Rimm, MD, PhD; Sarah B. Goldberg, MD, MPH; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
P137 | Development and high specification validation of a recombinant rabbit monoclonal antibody to accurately detect human PD-L2 expression in FFPE tissue sections by immunohistochemistry | Simon Renshaw; Will Howat, PhD; Subham Basu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immunoscore; Proteomics; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P138 | Review of evidence for predictive value of microsatellite instability/mismatch repair status in response to non-anti-PD-(L)1 therapies in patients with advanced or recurrent endometrial cancer | Cara Mathews, MD; Ellie Im; Liliana Alfaya; Cara Mathews, MD; Cara Mathews, MD; Karin Travers; Craig Gibson; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Targeted therapy |
P139 | Expression of GITR and GITR-L by Head and Neck Squamous Cell Cancer | Rachna L. Moudgil, MS; Christopher C. Paustian, PhD; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Carlo B. Bifulco, MD; Marcus A. Couey, MD, DDS; Traci L. Hilton, PhD; Bernard A. Fox, PhD; Rom Leidner, MD; R. Bryan Bell, DDS, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Costimulation; Immune contexture; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; Tumor stroma |
P140 | Myeloid cell contexture and IL-8 expression as a candidate immunotherapy target in Non-Small Cell Lung Cancer (NSCLC). | Venkata Vamsi Nagineni, MD; Kurt A. Schalper, MD, PhD; Shruti Desai, PhD; Ignacio Melero, MD; Miguel F. Sanmamed, MD, PhD; Richa Gupta; Roy S. Herbst, MD, PhD; Venkata Vamsi Nagineni, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Granulocyte; Targeted therapy; Tumor microenvironment; Tumor stroma |
P141 | One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining | Harsha A. Ranganath, MD; Amit Jain; Justin R. Smith; Julie Ryder; Amina Chaudry; Emily Miller; Felicia Hare; Poojitha Valasareddy; Rob Seitz; David R. Hout; Brock L. Schweitzer; Tyler J. Nielsen; Janice Mullins; Gregory Vidal; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P142 | Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer (NSCLC) using EpiSwitchTM epigenetic profiling | Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy |
P143 | Development and Validation of Baseline Predictive Biomarkers for Response to Immuno-Checkpoint Treatments in the Context of Multi-line and Multi-Therapy Cohorts using EpiSwitchTM epigenetic profiling. | Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy |
P144 | Quantification of tumor-stroma-immune contexture by multiplex fluorescent immunohistochemistry and whole-slide digital image analysis | Adriana Racolta, PhD; Mehrnoush Khojasteh, PhD; Jennifer Giltnane; Antony Hubbard, BS; Hongjun Zhang; Miriam Matei; Jessica Baumann; Wenjun Zhang, MD, PhD; Tsu-Shuen Tsao, PhD; Hartmut Koeppen; Lisa Ryner; Xingwei Wang; Jim Martin; Auranuch Lorsakul; Ilya Ravkin; Smadar Shiffman; Lidija Pestic-Dragovich; Lei Tang, PhD; Yulei Wang, BA PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P851 | Identifying potential predictive biomarkers from plasma exosomes and adoptive T cells that differentiate short and long-term metastatic nasopharyngeal cancer survivors treated with chemotherapy and virus-specific T cells | Timothy Shuen, Who-Whong WANG, PhD, Han Chong Toh, MBBChir, Janice Lim, Cherlyn Tan, Jennie Kosasih, Rachael Cheong | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Gene expression; Solid tumors; T cell |
P852 | Transcriptomic analysis of dysfunctional CD8+ TILs in melanoma identifies bile acid and MTOR pathways as novel potential immunotherapy targets | Cheryl Cameron, PhD, Brian Richardson, Jackelyn Golden, Lukas Pfannensttiel, Michael Cartwright, Yousef Moustafa, Samjhana Thapaliya, Gustavo Roversi, Yee Peng Phoon, Mark Cameron, Brian Gastman, MD, Cheryl Cameron, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P853 | Single Cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients | Chuan Li, Yee Peng Phoon, Keaton Karlinsey, Ye Tian, Samjhana Thapaliya, Lili Qu, Mark Cameron, Cheryl Cameron, PhD, Antoine Menoret, Pauline Funchain, MD, Jung-Min Song, RN, CNS, C. Marcela Diaz-Montero, Annabelle Rodriguez, Christopher Bonin, Anthony Vella, Beiyan Zhou, Brian Gastman, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |